benserazide has been researched along with tolcapone in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 15 (78.95) | 18.2507 |
| 2000's | 1 (5.26) | 29.6817 |
| 2010's | 3 (15.79) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Acquas, E; Carboni, E; Da Prada, M; de Ree, RH; Di Chiara, G | 1 |
| Andersson, Y; Antoni, G; Bjurling, P; Hartvig, P; Långström, B; Tedroff, J | 1 |
| Da Prada, M | 1 |
| Colzi, A; Da Prada, M; Zürcher, G | 1 |
| Fukazawa, H; Funaki, T; Kuruma, I; Onodera, H; Tagami, C; Tsukamoto, Y; Ushiyama, N | 1 |
| Da Prada, M; Napolitano, A; Zürcher, G | 1 |
| Himori, N; Mishima, K | 1 |
| Hazemeijer, I; Korf, J; Lakke, JP; Verhagen-Kamerbeek, WD | 1 |
| Da Prada, M; Dingemanse, J; Zürcher, G | 1 |
| Dubuis, R; Limousin, P; Perret, JE; Pfefen, JP; Pollak, P; Tournier-Gervason, CL | 1 |
| Aitken, J; Fotteler, B; Jorga, K; Nielsen, T; Schmitt, M; Zürcher, G | 1 |
| Goetz, CG | 1 |
| Baas, H; Beiske, AG; Ghika, J; Jackson, M; Oertel, WH; Poewe, W; Ransmayr, G | 1 |
| Beiske, A; Fotteler, B; Jorga, KM; Larsen, JP; Moe, B; Schleimer, M; Schmitt, M | 1 |
| Crevoisier, C; Gasser, UE; Hovens, SE; Jorga, K; van Giersbergen, PL | 1 |
| Banken, L; Fotteler, B; Jorga, K; Snell, P; Steimer, JL | 1 |
| Adamiak, U; Bialecka, M; Gawronska-Szklarz, B; Kaldonska, M; Klodowska-Duda, G; Safranow, K; Wyska, E | 1 |
| Eggert, K; Eichhorn, T; Oertel, WH; Ries, V; Selzer, R | 1 |
1 review(s) available for benserazide and tolcapone
| Article | Year |
|---|---|
New approaches to the treatment of age-related brain disorders.
Topics: Aging; Alzheimer Disease; Benserazide; Benzophenones; Catechol O-Methyltransferase Inhibitors; Drug Combinations; Enzyme Inhibitors; Humans; Levodopa; Monoamine Oxidase Inhibitors; Nitrophenols; Parkinson Disease; Picolinic Acids; Tolcapone | 1991 |
8 trial(s) available for benserazide and tolcapone
| Article | Year |
|---|---|
Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benserazide; Benzophenones; Catechol O-Methyltransferase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Motor Activity; Nitrophenols; Parkinson Disease; Placebos; Tolcapone | 1995 |
The effect of COMT inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa/benserazide formulations.
Topics: Adjuvants, Pharmaceutic; Adult; Antiparkinson Agents; Benserazide; Benzophenones; Biological Availability; Catechol O-Methyltransferase Inhibitors; Cross-Over Studies; Delayed-Action Preparations; Dopamine Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Levodopa; Male; Nitrophenols; Reference Values; Tolcapone | 1997 |
Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
Topics: Aged; Antiparkinson Agents; Benserazide; Benzophenones; Catechol O-Methyltransferase Inhibitors; Diarrhea; Dopamine Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Europe; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Tolcapone; Treatment Outcome | 1998 |
The effect of tolcapone on the pharmacokinetics of benserazide.
Topics: Aged; Antiparkinson Agents; Benserazide; Benzophenones; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Time Factors; Tolcapone; Tyrosine | 1999 |
COMT inhibition by tolcapone further improves levodopa pharmacokinetics when combined with a dual-release formulation of levodopa/benserazide. A novel principle in the treatment of Parkinson's disease.
Topics: Adolescent; Adult; Antiparkinson Agents; Benserazide; Benzophenones; Catechol O-Methyltransferase; Chromatography, High Pressure Liquid; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Nitrophenols; Parkinson Disease; Time Factors; Tolcapone | 1999 |
Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Area Under Curve; Benserazide; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Models, Statistical; Nitrophenols; Parkinson Disease; Population; Risk Factors; Single-Blind Method; Tolcapone | 2000 |
Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Topics: Age of Onset; Aged; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Drug Combinations; Drug Therapy, Combination; Dyskinesias; Enzyme Inhibitors; Female; Half-Life; Humans; Levodopa; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Nitrophenols; Parkinson Disease; Severity of Illness Index; Tolcapone; Tyrosine | 2010 |
Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study.
Topics: Aged; Ambulatory Care Facilities; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Dyskinesias; Enzyme Inhibitors; Feasibility Studies; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Severity of Illness Index; Time Factors; Tolcapone; Treatment Outcome | 2010 |
10 other study(ies) available for benserazide and tolcapone
| Article | Year |
|---|---|
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Extracellular concentrations of dopamine and metabolites in the rat caudate after oral administration of a novel catechol-O-methyltransferase inhibitor Ro 40-7592.
Topics: Administration, Oral; Animals; Benserazide; Benzophenones; Catechol O-Methyltransferase Inhibitors; Caudate Nucleus; Dopamine; Drug Interactions; Extracellular Space; Levodopa; Male; Nitrophenols; Osmolar Concentration; Rats; Rats, Inbred Strains; Tetrodotoxin; Tolcapone | 1992 |
Central action of benserazide after COMT inhibition demonstrated in vivo by PET.
Topics: Animals; Benserazide; Benzophenones; Brain; Catechol O-Methyltransferase Inhibitors; Levodopa; Macaca mulatta; Nitrophenols; Parkinson Disease; Tolcapone; Tomography, Emission-Computed | 1991 |
Ro 40-7592: inhibition of COMT in rat brain and extracerebral tissues.
Topics: Animals; Benserazide; Benzophenones; Biological Availability; Brain; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Chromatography, High Pressure Liquid; Electrochemistry; Erythrocytes; Half-Life; In Vitro Techniques; Levodopa; Male; Nitrophenols; Norepinephrine; Rats; Rats, Inbred Strains; Tolcapone; Tyrosine | 1990 |
Lack of an effect of Madopar on the disposition of tolcapone and its 3-O-methylated metabolite in rats.
Topics: Animals; Benserazide; Benzophenones; Biotransformation; Catechol O-Methyltransferase Inhibitors; Drug Combinations; Enzyme Inhibitors; Half-Life; Injections, Intravenous; Levodopa; Male; Methylation; Nitrophenols; Rats; Rats, Sprague-Dawley; S-Adenosylmethionine; Tissue Distribution; Tolcapone | 1995 |
Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-dopa and dopamine in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide; Benzophenones; Catechol O-Methyltransferase Inhibitors; Chromatography, High Pressure Liquid; Dopamine; Dose-Response Relationship, Drug; Extracellular Space; Homovanillic Acid; Levodopa; Male; Methylation; Microdialysis; Neostriatum; Nitrophenols; Rats; Tolcapone | 1995 |
The COMT inhibitor tolcapone potentiates the anticataleptic effect of Madopar in MPP(+)-lesioned mice.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Benserazide; Benzophenones; Catalepsy; Catechol O-Methyltransferase Inhibitors; Drug Combinations; Drug Synergism; Haloperidol; Kinetics; Levodopa; Male; Mice; Mice, Inbred C57BL; Nitrophenols; Tolcapone; Tyrosine | 1994 |
Attenuation of haloperidol-induced catalepsy by noradrenaline and L-threo-DOPS.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Benzophenones; Catalepsy; Catechol O-Methyltransferase Inhibitors; Droxidopa; Drug Interactions; Haloperidol; Male; Nitrophenols; Norepinephrine; Postural Balance; Rats; Rats, Wistar; Tolcapone | 1993 |
Potent COMT inhibition by Ro 40-7592 in the periphery and in the brain. Preclinical and clinical findings.
Topics: Animals; Benserazide; Benzophenones; Brain; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Dose-Response Relationship, Drug; Erythrocytes; Homovanillic Acid; Humans; Levodopa; Male; Nitrophenols; Peripheral Nerves; Rats; S-Adenosylhomocysteine; S-Adenosylmethionine; Tolcapone | 1993 |
Highlights of the North American and European experiences.
Topics: Antiparkinson Agents; Benserazide; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dopamine Agents; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Enzyme Inhibitors; Europe; Humans; Levodopa; Nitrophenols; North America; Parkinson Disease; Randomized Controlled Trials as Topic; Tolcapone | 1998 |